Beijing Biostar Pharmaceuticals Updates Board and Committee Structure After Director Resignation

An announcement from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) is now available.

Beijing Biostar Pharmaceuticals announced an updated composition of its board of directors and board committees, effective 29 April 2026, following the resignation of director Dr. Meng Songdong. The list clarifies the roles of executive, non-executive and independent non-executive directors, including committee chairpersons and members, aiming to ensure continuity in audit, nomination, remuneration and strategy oversight.

The reshuffled board keeps Dr. Tang Li as chairperson and chief scientific and marketing officer, with Dr. Qiu Rongguo continuing as vice-chairperson and chief executive officer, indicating stability in top management despite the change. By specifying committee leadership and membership, the company signals an emphasis on clear corporate governance responsibilities, which may reassure investors and other stakeholders about oversight and decision-making processes.

More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H

Beijing Biostar Pharmaceuticals Co., Ltd. is a joint stock biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2563. The company focuses on pharmaceutical research, development and commercialization, with a governance structure that includes executive, non-executive and independent non-executive directors overseeing its strategic and operational direction.

Average Trading Volume: 22,984

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.42B

For detailed information about 2563 stock, go to TipRanks’ Stock Analysis page.